Back to results
US 9,849,122 B2Granted
Combination therapy
AssigneeAerie Pharmaceuticals, Inc.
InventorsCasey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Life of this patent
Estimating the term…
Abstract
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
Claims21
A compound according to formula (II):
- or a pharmaceutically acceptable salt thereof, wherein:
- Y is phenylene;
- B is —NR1R2 or —CH2NR1R2;
- R1 and R2 are each independently hydrogen or C1-C4 alkyl;
- X1 and X2 are hydrogen;
- and
- PG is an acyl radical of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, unoprostone, or PGF2α.
4 more elements
A compound, wherein the compound is:
- or a pharmaceutically acceptable salt thereof.
A compound according to formula (II):
- or a pharmaceutically acceptable salt thereof;
- wherein
- Y is phenylene;
- B is —CH2NR1R2;
- R1 and R2 are hydrogen;
- X1 and X2 are hydrogen;
- and
- PG is an acyl radical of latanoprost.
5 more elements
Dependencies are inferred from the claim text.